Ikarian Capital, LLC Mereo Biopharma Group PLC Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.15 - $1.67 $345,000 - $501,000	-300,000 Reduced 33.64%	591,676 $763,000
Q2 2023 Aug 14, 2023	BUY	$0.79 - $1.43 $704,424 - $1.28 Million	891,676 New	891,676 $1.18 Million
Q2 2022 Aug 12, 2022	SELL	$0.33 - $1.69 $99,000 - $507,000	-300,000 Reduced 32.76%	615,856 $199,000
Q1 2022 May 13, 2022	BUY	$1.04 - $1.7 $64,663 - $105,699	62,176 Added 7.28%	915,856 $318,000
Q4 2021 Feb 14, 2022	SELL	$1.51 - $2.59 $75,500 - $129,500	-50,000 Reduced 5.53%	853,680 $307,000
Q3 2021 Nov 15, 2021	SELL	$2.2 - $3.17 $89,381 - $128,790	-40,628 Reduced 4.3%	903,680 $322,000
Q2 2021 Aug 16, 2021	SELL	$2.94 - $4.08 $593,880 - $824,160	-202,000 Reduced 17.62%	944,308 $346,000
Q4 2020 Feb 12, 2021	SELL	$1.95 - $3.6 $97,500 - $180,000	-50,000 Reduced 4.18%	1,146,308 $416,000
Q3 2020 Nov 16, 2020	BUY	$2.55 - $3.29 $3.05 Million - $3.94 Million	1,196,308 New	1,196,308 $688,000

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $419M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.